SCHEMBL10018774

SCHEMBL10018774

O=C1Nc2ccccc2C1(O)c1ccc2occc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
CASP6 P55212 1/20 0.54
KMT2A Q03164 4/20 0.48
MEN1 O00255 2/20 0.48
CHRM2 P08172 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
KCNH2 Q12809 1/20 0.40
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
XBP1 P17861 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
EPM2A O95278 1/20 0.38
PTPRC P08575 1/20 0.38
PTPN6 P29350 1/20 0.38
CDC14A Q9UNH5 1/20 0.38
PTPN22 Q9Y2R2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
TSHR P16473 1/20 0.38
CTNNB1 P35222 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10018773 0.82 PDK2 (0.43) POLBCASP6KMT2AMEN1CHRM2
SCHEMBL10018770 0.82 LMNA (0.38) POLBCASP6KMT2AMEN1CHRM2
SCHEMBL10018775 0.80 PDK2 (0.38) POLBCASP6KMT2AMEN1CHRM2
SCHEMBL22169992 0.76 CTNNB1 (0.38) EPM2APTPRCPTPN6CDC14APTPN22
SCHEMBL16501831 0.76 EPM2A (0.34) POLBCASP6KMT2AMEN1CHRM2
SCHEMBL627521 0.75 ALDH1A1 (0.39) MAPTALDH1A1BRD4
SCHEMBL24281054 0.73 POLB (0.77) POLBCASP6KMT2AMEN1CHRM2
SCHEMBL10018772 0.73 BRD4 (0.48) KMT2AMEN1CHRM2ADORA3KCNH2
SCHEMBL18025761 0.73 KMT2A (0.66) POLBCASP6KMT2AMEN1CHRM2
SCHEMBL18552443 0.73 KMT2A (0.66) POLBCASP6KMT2AMEN1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9889130-B2 Substituted 3-benzofuranyl-indol-2-one-3-acetamididopiperazine derivatives, preparation thereof, and therapeutic use thereof SANOFI (FR) 2018-02-13 US disclosed
US-9889130-B2 Substituted 3-benzofuranyl-indol-2-one-3-acetamididopiperazine derivatives, preparation thereof, and therapeutic use thereof SANOFI (FR) 2018-02-13 US disclosed
US-20170119761-A1 SUBSTITUTED 3-BENZOFURANYL-INDOL-2-ONE-3-ACETAMIDIDOPIPERAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2017-05-04 US disclosed
US-20170119761-A1 SUBSTITUTED 3-BENZOFURANYL-INDOL-2-ONE-3-ACETAMIDIDOPIPERAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2017-05-04 US disclosed
US-20120040996-A1 3-BENZOFURANYL-INDOL-2-ONE DERIVATIVES SUBSTITUTED AT THE 3 POSITION, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-02-16 US disclosed
US-20110312972-A1 SUBSTITUTED 3-BENZOFURANYL-INDOL-2-ONE-3-ACETAMIDIDOPIPERAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170119761-A1 SUBSTITUTED 3-BENZOFURANYL-INDOL-2-ONE-3-ACETAMIDIDOPIPERAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF IDO1, TPH1, QDPR POLB 4248/4885CASP6 3095/4885KMT2A 3127/4885
US-20110312972-A1 SUBSTITUTED 3-BENZOFURANYL-INDOL-2-ONE-3-ACETAMIDIDOPIPERAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF IDO1, TPH1, QDPR POLB 4248/4885CASP6 3095/4885KMT2A 3127/4885
US-20120040996-A1 3-BENZOFURANYL-INDOL-2-ONE DERIVATIVES SUBSTITUTED AT THE 3 POSITION, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF TPH1, IDO1, TPH2 POLB 3315/4885CASP6 3106/4885KMT2A 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.